from innate immunity
to patient solutions

Equaly’s technology platform modulates immune responses based on antigen-specific cells of the innate immune system. This opens the door to better biologicals and new immunotherapies for cancer, infectious diseases and auto-immune diseases.

How does it work?

The innate immune system is the body’s first line of defense, providing a fast and powerful reaction to health threats. Traditionally, this system was thought to be non-antigen-specific and was therefore not considered for therapeutic use, due to the risk of off-target effects.

Newly discovered mechanisms have now shown that a subpopulation of cells belonging to the innate immune system can be triggered by proteins and elicit a specific response. These activated cells not only exert a direct effect themselves, but are also key to modulating the adaptive immune system’s response.

Based on these insights, Equaly is the first company to unlock the therapeutic potential of the innate immune system.

Our technology platforms

Equaly’s technology opens up a whole new approach to developing and improving therapies. Our platform can be used to:

Partnering with us

Are you interested in working with us? Discover how we approach partnerships to develop new solutions.

How can we


As a pioneer in innate immunity, Equaly is fully dedicated to help patients facing various unsettled clinical situations. These include autoimmunity, tumors, chronic intracellular infections and/or specific genetic diseases.